IMTX
Immatics NV
NASDAQ · Healthcare · Biotechnology · DE
$8.62
−2.27%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$8.76
From 52W high−27.38%
Volume758969.00
Market cap$1.29B
P/E (TTM)—
P/S (TTM)26.9x
Div yield—
Key dataSep 18, 2026
Open
$8.76
From 52W high
−27.38%
Volume
758969.00
Market cap
$1.29B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.8x
P/E (TTM)
—
RSI (14)
38.5
MomentumView details →
1D Return
−2.27%
YTD Return
−18.66%
SummaryUpdated Jun 1, 2026
Immatics N.V. (NASDAQ:IMTX) is a clinical-stage biopharmaceutical company founded in 2000 and headquartered in Tübingen, Germany. The company went public in December 2018 and focuses on developing innovative T cell receptor (TCR) based immunotherapies for cancer treatment. Immatics operates at the cutting edge of precision oncology, leveraging its proprietary technology platforms to identify cancer-specific targets and develop personalized immunotherapies. The company has established strategic partnerships with major pharmaceutical companies including GlaxoSmithKline, Genmab, and previously with Celgene, positioning itself as a leader in the emerging field of TCR-based cancer immunotherapy.
Similar companies
Latest newsMore news →